News
BMRN
66.49
+1.16%
0.76
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
NASDAQ · 5h ago
BMRN or TECH: Which Is the Better Value Stock Right Now?
NASDAQ · 6h ago
BUZZ-Gene therapy makers set to end 2024 in the red
Reuters · 12/31/2024 18:15
Top U.S. health care mid-cap stocks and their Quant Ratings
Seeking Alpha · 12/31/2024 15:46
Why did Pfizer's exit from the gene therapy program hit Sangamo hard?
Seeking Alpha · 12/31/2024 14:55
BUZZ-Sangamo Therapeutics plunges after Pfizer terminates partnership
Reuters · 12/31/2024 13:41
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
NASDAQ · 12/31/2024 10:55
TD Cowen ‘disappointed’ Pfizer ended Sangamo collaboration
TipRanks · 12/31/2024 09:35
Penny Stock Sangamo (SGMO) Nosedives as Pfizer Terminates Partnership
TipRanks · 12/31/2024 07:49
Notable ETF Inflow Detected - XBI, NBIX, BMRN, UTHR
NASDAQ · 12/30/2024 15:49
Weekly Report: what happened at BMRN last week (1223-1227)?
Weekly Report · 12/30/2024 09:12
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Simply Wall St · 12/26/2024 19:06
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
NASDAQ · 12/24/2024 14:45
Is Incyte Stock Outperforming the Dow?
Barchart · 12/24/2024 06:28
First Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN)
NASDAQ · 12/23/2024 17:35
Weekly Report: what happened at BMRN last week (1216-1220)?
Weekly Report · 12/23/2024 09:12
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
Barchart · 12/19/2024 08:42
The Take On Tyra Biosciences
Seeking Alpha · 12/17/2024 22:13
Worst performing stocks for tax loss selling – Wolfe
Seeking Alpha · 12/16/2024 19:59
Weekly Report: what happened at BMRN last week (1209-1213)?
Weekly Report · 12/16/2024 09:13
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.